Back HCV Treatment

HCV Treatment

EASL 2014: 88% of Previous Relapsers Cured with Simeprevir Triple Therapy

Almost 90% of European patients who had relapsed after previous treatment with pegylated interferon and ribavirin were cured of hepatitis C after 24 weeks of treatment with the protease inhibitor simeprevir (Olysio) combined with pegylated interferon/ribavirin, according to a presentation Thursday at the 49th EASL International Liver Congress (EASL 2014) in London.

alt

Read more:

EASL 2014: Sofosbuvir + Ledipasvir Produces Early Cure for 100% of HIV/HCV Coinfected Patients

Treatment for 12 weeks with a coformulation of sofosbuvir plus ledipasvir led to sustained response for all HIV/HCV coinfected individuals with genotype 1 hepatitis C followed for 12 weeks post-treatment, according to interim findings from the ERADICATE study presented at the 49thEASL International Liver Congress (EASL 2014) this week in London.

alt

Read more:

EASL 2014: International Liver Congress Starts this Week in London

The European Association for the Study of the Liver's International Liver Congress (EASL 2014) takes place April 9-13 at the ExCel Centre in London. The annual conference is one of the key annual scientific meetings covering viral hepatitis and its complications. Also on Thursday, the World Health Organization (WHO) will release new global guidelines for hepatitis C.

alt

Read more:

EASL 2014: WHO Recommends Global Use of Newest Hepatitis C Drugs, Urges Price Reductions

The World Health Organization has issued global treatment guidelines for hepatitis C, strongly recommending the use of the new direct-acting antivirals sofosbuvir (Sovaldi) with ribavirin for HCV genotypes 1, 2, 3, and 4, or simeprevir (Olysio) with pegylated interferon interferon and ribavirin for genotype 1 infection. The WHO guidelines were released to coincide with the 49th International Liver Congress this week in London. New guidelines from the European Association for the Study of the Liver (EASL) will be released on Saturday.

alt

Read more:

Bristol-Myers Squibb Requests FDA Approval of Daclatasvir and Asunaprevir

Bristol-Myers Squibb has submitted New Drug Applications asking the U.S. Food and Drug Administration (FDA) to approve its experimental hepatitis C virus (HCV) NS5A inhibitor daclatasvir and HCV protease inhibitor asunaprevir, the company announced this week.

alt

Read more: